ABPI to Challenge NICE Budget Impact Test in Court

The Association of the British Pharmaceutical Industry (ABPI) will be challenging NICE’s implementation of the budget impact test which they introduced in April 2017.

Treatments which represent a significant burden on the NHS (exceeding the £20m threshold in any one of the first three years) trigger negotiations between NHS England and the company regardless of whether the treatment is cost-effective or not. The ABPI’s chief executive, Mike Thompson, said: “These new arrangements will delay access to cost-effective medicines and deny treatments to patients suffering from rare diseases.”

ABPI plans to challenge this via a Judicial Review to reverse “inappropriate and unworkable” changes made to the assessment of medicines for very rare diseases.

Read more on the story here.

Tagged with

Published 11. July 2017 in News UK